Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 3, 2009, Pages 595-602

  Mohapatra, Subhra ^a,b   Chu, Baoky ^a   Zhao, Xiuhua ^a   Djeu, Julie ^a   Cheng, Jin Q ^a   Pledger, W Jackson ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AKT; cdk9; PC3; Prostate cancer; Roscovitine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; API 2; BH3 PROTEIN; BIM PROTEIN; CASPASE 9; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; DOMINANT NEGATIVE CYCLIN DEPENDENT KINASE 9; PROTEIN BAX; PROTEIN KINASE B INHIBITOR; RECOMBINANT ENZYME; ROSCOVITINE; SMALL INTERFERING RNA; TRICIRIBINE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; MITOCHONDRION; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 9; CELL LINE, TUMOR; CHLORPROPAMIDE; CHROMONES; CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DNA; DRUG SYNERGISM; HUMANS; MALE; MEMBRANE PROTEINS; MITOCHONDRIA; MORPHOLINES; NUCLEIC ACID SYNTHESIS INHIBITORS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; RNA, SMALL INTERFERING; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 58149312591     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.07.013     Document Type: Article

References (49)

1. Bello D., Webber M.M., Kleinman H.K., Wartinger D.D., and Rhim J.S. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18 (1997) 1215-1223
2. Benson C., White J., Bono J.D., O'Donnell A., Raynaud F., Cruickshank C., et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 96 (2007) 29-37
3. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol. 39 (2003) 615-647
4. Bossy-Wetzel E., Newmeyer D.D., and Green D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 17 (1998) 37-49
5. Cai D., Latham Jr. V.M., Zhang X., and Shapiro G.I. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 66 (2006) 9270-9280
6. Carson J.P., Kulik G., and Weber M.J. Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res. 59 (1999) 1449-1453
7. Chang H.Y., and Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64 (2000) 821-846
8. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17 (1998) 2215-2223
9. Dlugosz P.J., Billen L.P., Annis M.G., Zhu W., Zhang Z., Lin J., et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 25 (2006) 2287-2296
10. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
11. Feun L.G., Blessing J.A., Barrett R.J., and Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 16 (1993) 506-508
12. Feun L.G., Savaraj N., Bodey G.P., Lu K., Yap B.S., Ajani J.A., et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 44 (1984) 3608-3612
13. Fischer P.M., and Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin. Investig. Drugs 14 (2005) 457-477
14. Gardai S.J., Hildeman D.A., Frankel S.K., Whitlock B.B., Frasch S.C., Borregaard N., et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 279 (2004) 21085-21095
15. Gold M.O., Yang X., Herrmann C.H., and Rice A.P. PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 72 (1998) 4448-4453
16. Griffiths G.J., Dubrez L., Morgan C.P., Jones N.A., Whitehouse J., Corfe B.M., et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 144 (1999) 903-914
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
18. Kim E.H., Kim S.U., Shin D.Y., and Choi K.S. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23 (2004) 446-456
19. Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465-7474
20. Makin G.W., Corfe B.M., Griffiths G.J., Thistlethwaite A., Hickman J.A., and Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J. 20 (2001) 6306-6315
21. Marciniak R.A., and Sharp P.A. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 10 (1991) 4189-4196
22. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
23. Meinhart A., Kamenski T., Hoeppner S., Baumli S., and Cramer P. A structural perspective of CTD function. Genes Dev. 19 (2005) 1401-1415
24. Mohapatra S., Chu B., Wei S., Djeu J., Epling-Burnette P.K., Loughran T., et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 63 (2003) 8523-8530
25. Mohapatra S., Chu B., Zhao X., and Pledger W.J. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 65 (2005) 7717-7723
26. Monaco E.A., Beaman-Hall C.M., Mathur A., and Vallano M.L. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem. Pharmacol. 67 (2004) 1947-1964
27. Munoz-Pinedo C., Guio-Carrion A., Goldstein J.C., Fitzgerald P., Newmeyer D.D., and Green D.R. Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in duration. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11573-11578
28. Pettaway C.A., Pathak S., Greene G., Ramirez E., Wilson M.R., Killion J.J., et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2 (1996) 1627-1636
29. Phatnani H.P., and Greenleaf A.L. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 20 (2006) 2922-2936
30. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1563-1568
31. Priulla M., Calastretti A., Bruno P., Azzariti A., Paradiso A., Canti G., et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67 (2007) 782-789
32. EL apoptotic function. J. Biol. Chem. 281 (2006) 813-823
33. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13 (2006) 1378-1386
34. Shen M.M., and Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 67 (2007) 6535-6538
35. Shukla S., Maclennan G.T., Hartman D.J., Fu P., Resnick M.I., and Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer 121 (2007) 1424-1432
36. Soucie E.L., Annis M.G., Sedivy J., Filmus J., Leber B., Andrews D.W., et al. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. 21 (2001) 4725-4736
37. Strasser A., O'Connor L., and Dixit V.M. Apoptosis signaling. Annu. Rev. Biochem. 69 (2000) 217-245
38. Tsuruta F., Masuyama N., and Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J. Biol. Chem. 277 (2002) 14040-14047
39. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
40. Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58 (1998) 2720-2723
41. Wang D., de la Fuente C., Deng L., Wang L., Zilberman I., Eadie C., et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75 (2001) 7266-7279
42. Wilkinson J.C., Cepero E., Boise L.H., and Duckett C.S. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol. Cell. Biol. 24 (2004) 7003-7014
43. Wolter K.G., Hsu Y.T., Smith C.L., Nechushtan A., Xi X.G., and Youle R.J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139 (1997) 1281-1292
44. Xin M., and Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J. Biol. Chem. 280 (2005) 10781-10789
45. Yamaguchi H., and Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20 (2001) 7779-7786
46. L mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J. Biol. Chem. 278 (2003) 25872-25878
47. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64 (2004) 4394-4399
48. Yu C., Rahmani M., Dai Y., Conrad D., Krystal G., Dent P., et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 63 (2003) 1822-1833
49. Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., and Wang C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 7 (2005) 909-915